Scholar Rock is trading 4.3% down now at $53.04 after shares rallied sharply in extended trading following Friday’s FDA approval of ISEMBYLD, its first approved therapy for SMA.
- U.S. markets are weakening, with the S&P 500 down 0.75% and Nasdaq Composite down 0.93%.
- Investors may be locking in gains while assessing commercialization prospects.
- Truist raised its price target to $76.